Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy
Open Access
- 26 July 2011
- journal article
- review article
- Published by Hindawi Limited in Advances in Hematology
- Vol. 2012, 1-12
- https://doi.org/10.1155/2012/469592
Abstract
In the recent years, the discovery of a series of mutations in patients with myeloid malignancies has provided insight into the pathogenesis of myelodysplastic syndromes (MDSs), myeloproliferative neoplasms (MPNs), and acute myeloid leukemia (AML). Among these alterations have been mutations in genes, such asIDH1/2,TET2,DNMT3A, andEZH2, which appear to affect DNA and/or histone lysine methylation. Large clinical correlative studies are beginning to decipher the clinical importance, prevalence, and potential prognostic significance of these mutations. Additionally, burgeoning insight into the role of epigenetics in the pathogenesis of myeloid malignancies has prompted increased interest in development of novel therapies which target DNA and histone posttranslational modifications. DNA demethylating agents have been demonstrated to be clinically active in a subset of patients with MDS and AML and are used extensively. However, newer, more specific agents which alter DNA and histone modification are under preclinical study and development and are likely to expand our therapeutic options for these diseases in the near future. Here, we review the current understanding of the clinical importance of these newly discovered mutations in AML and MDS patients. We also discuss exciting developments in DNA methyltransferase inhibitor strategies and the prospect of novel histone lysine methyltransferase inhibitors.Keywords
This publication has 97 references indexed in Scilit:
- Hydroxylation of 5-Methylcytosine by TET1 Promotes Active DNA Demethylation in the Adult BrainCell, 2011
- Recurrent DNMT3A mutations in patients with myelodysplastic syndromesLeukemia, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosisLeukemia, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid LeukemiaCancer Cell, 2010
- Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluationBioorganic & Medicinal Chemistry, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- H3K79 Methylation Profiles Define Murine and Human MLL-AF4 LeukemiasCancer Cell, 2008
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004